Bayer AG, Pharmaceuticals, Berlin, Germany
Represented by the Management Board:
Werner Baumann, Chairman
Liam Condon, Hartmut Klusik, Kemal Malik,
Wolfgang Nickl, Stefan Oelrich, Heiko Schipper
phone: +49-30-468-11 11
for E-mail contact please click here .
Entry in the Commercial Register of the Cologne District Court (Amtsgericht): HRB 48248
Turnover tax ID no.: DE 123659859
Strategic Marketing, Pharmaceuticals
KOGENATE FS is an Antihemophilic Factor (Recombinant) indicated for:
KOVALTRY Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:
JIVI antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:
KOGENATE FS, KOVALTRY, and JIVI are not indicated for the treatment of von Willebrand disease.
In clinical trials with: